Influenza Virus Infection Enhances Antibody-Mediated NK Cell Functions via Type I Interferon-Dependent Pathways.
A549 Cells
Antibodies, Viral
/ immunology
Antibody-Dependent Cell Cytotoxicity
/ immunology
Cell Line
Cytokines
/ immunology
Humans
Influenza A Virus, H1N1 Subtype
/ immunology
Influenza A Virus, H3N2 Subtype
/ immunology
Influenza, Human
/ immunology
Interferon Type I
/ metabolism
Killer Cells, Natural
/ immunology
ADCC
NK cell
influenza
interferons
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
01 03 2019
01 03 2019
Historique:
received:
26
11
2018
accepted:
29
11
2018
pubmed:
14
12
2018
medline:
21
11
2019
entrez:
14
12
2018
Statut:
epublish
Résumé
Natural killer (NK) cells are an important component in the control of influenza virus infection, acting to both clear virus-infected cells and release antiviral cytokines. Engagement of CD16 on NK cells by antibody-coated influenza virus-infected cells results in antibody-dependent cellular cytotoxicity (ADCC). Increasing the potency of antibody-mediated NK cell activity could ultimately lead to improved control of influenza virus infection. To understand if NK cells can be functionally enhanced following exposure to influenza virus-infected cells, we cocultured human peripheral blood mononuclear cells (PBMCs) with influenza virus-infected human alveolar epithelial (A549) cells and evaluated the capacity of NK cells to mediate antibody-dependent functions. Preincubation of PBMCs with influenza virus-infected cells markedly enhanced the ability of NK cells to respond to immune complexes containing hemagglutinin (HA) and anti-HA antibodies or transformed allogeneic cells in the presence or absence of a therapeutic monoclonal antibody. Cytokine multiplex, RNA sequencing, supernatant transfer, Transwell, and cytokine-blocking/cytokine supplementation experiments showed that type I interferons released from PBMCs were primarily responsible for the influenza virus-induced enhancement of antibody-mediated NK cell functions. Importantly, the influenza virus-mediated increase in antibody-dependent NK cell functionality was mimicked by the type I interferon agonist poly(I·C). We conclude that the type I interferon secretion induced by influenza virus infection enhances the capacity of NK cells to mediate ADCC and that this pathway could be manipulated to alter the potency of anti-influenza virus therapies and vaccines.
Identifiants
pubmed: 30541850
pii: JVI.02090-18
doi: 10.1128/JVI.02090-18
pmc: PMC6384076
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Cytokines
0
Interferon Type I
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
J Immunol. 2013 Feb 15;190(4):1837-48
pubmed: 23319732
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Immunity. 2005 Jul;23(1):19-28
pubmed: 16039576
Immunotargets Ther. 2015 May 15;4:91-100
pubmed: 27471715
Science. 2011 Aug 12;333(6044):850-6
pubmed: 21798894
Nature. 2001 Feb 22;409(6823):1055-60
pubmed: 11234016
J Immunol. 1978 Aug;121(2):532-8
pubmed: 150448
PLoS Pathog. 2013;9(4):e1003256
pubmed: 23592984
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Adv Immunol. 1988;42:181-211
pubmed: 3284289
Antimicrob Agents Chemother. 2017 Oct 24;61(11):
pubmed: 28807912
J Immunol. 2016 Jul 1;197(1):313-25
pubmed: 27233958
Science. 2012 Sep 14;337(6100):1343-8
pubmed: 22878502
PLoS One. 2016 Apr 28;11(4):e0154461
pubmed: 27124730
J Immunol. 1986 Feb 15;136(4):1435-41
pubmed: 3944461
Reg Immunol. 1988 Sep-Oct;1(2):100-5
pubmed: 3275212
Science. 2011 Aug 12;333(6044):843-50
pubmed: 21737702
Cell Host Microbe. 2016 Jun 8;19(6):800-13
pubmed: 27281570
Nat Immunol. 2006 May;7(5):517-23
pubmed: 16565719
J Immunol. 1983 May;130(5):2142-8
pubmed: 6339622
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11931-11936
pubmed: 27698132
Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5944-E5951
pubmed: 27647907
Immunol Cell Biol. 2014 Mar;92(3):256-62
pubmed: 24366517
Nat Med. 2014 Feb;20(2):143-51
pubmed: 24412922
Eur J Immunol. 2013 Apr;43(4):929-38
pubmed: 23436540
J Immunol. 2014 Jul 15;193(2):469-75
pubmed: 24994909
Blood. 2004 Jan 15;103(2):664-72
pubmed: 14504081
Vaccine. 2017 Nov 7;35(47):6451-6458
pubmed: 29029940
Blood. 2012 Jun 14;119(24):5640-9
pubmed: 22535666
J Immunol. 2005 Aug 1;175(3):1636-42
pubmed: 16034103
J Immunol. 2005 Jan 15;174(2):727-34
pubmed: 15634892
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Cell Host Microbe. 2017 Aug 9;22(2):193-206
pubmed: 28799905
Virology. 2010 Dec 20;408(2):146-58
pubmed: 20934196
J Clin Invest. 2016 Feb;126(2):605-10
pubmed: 26731473
Nat Med. 2015 Sep;21(9):1065-70
pubmed: 26301691
Vaccines (Basel). 2018 May 17;6(2):
pubmed: 29772781
AIDS. 2017 Jan 28;31(3):333-342
pubmed: 27835615
Science. 2004 Mar 5;303(5663):1529-31
pubmed: 14976261
Nat Methods. 2015 Apr;12(4):357-60
pubmed: 25751142
Science. 2015 Sep 18;349(6254):1301-6
pubmed: 26303961
Curr Opin Virol. 2017 Jun;24:60-69
pubmed: 28527859
Nat Commun. 2017 Oct 10;8(1):846
pubmed: 29018261
AIDS Res Hum Retroviruses. 2016 Oct/Nov;32(10-11):1089-1096
pubmed: 27487965
J Biol Chem. 2002 Jul 26;277(30):26733-40
pubmed: 11986321
PLoS One. 2015 Oct 26;10(10):e0140829
pubmed: 26501966
Nat Rev Immunol. 2014 May;14(5):315-28
pubmed: 24762827
J Immunol. 2007 Mar 15;178(6):3368-72
pubmed: 17339430
Amino Acids. 2010 May;38(5):1283-99
pubmed: 19882216
Eur J Immunol. 2001 Sep;31(9):2680-9
pubmed: 11536166
J Infect Dis. 2012 Jul 15;206(2):167-77
pubmed: 22561366
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
Immunol Cell Biol. 2011 Feb;89(2):216-24
pubmed: 20567250